ProKidney Corp. (PROK)
NASDAQ: PROK · Real-Time Price · USD
2.350
-0.020 (-0.84%)
Aug 14, 2025, 1:52 PM - Market open
ProKidney Revenue
ProKidney had revenue of $221.00K in the quarter ending June 30, 2025. This brings the company's revenue in the last twelve months to $527.00K. In the year 2024, ProKidney had annual revenue of $76.00K.
Revenue (ttm)
$527.00K
Revenue Growth
n/a
P/S Ratio
1,264.92
Revenue / Employee
$2,583
Employees
204
Market Cap
687.86M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
PROK News
- 1 day ago - ProKidney Reports Second Quarter 2025 Financial Results and Provides Regulatory and Clinical Updates - GlobeNewsWire
- 4 weeks ago - ProKidney Announces Alignment with the FDA on the Accelerated Approval Pathway for Rilparencel - GlobeNewsWire
- 5 weeks ago - ProKidney: What's Happening With PROK Stock? - Forbes
- 5 weeks ago - ProKidney to Participate in the H.C. Wainwright 4th Annual Kidney Virtual Conference - GlobeNewsWire
- 5 weeks ago - ProKidney's stock rockets on ‘intriguing' news, but analyst doesn't recommend buying - Market Watch
- 5 weeks ago - Gold Falls 1%; ProKidney Shares Spike Higher - Benzinga
- 5 weeks ago - Why Is Penny Stock ProKidney Trading Higher On Tuesday? - Benzinga
- 5 weeks ago - ProKidney Reports Statistically and Clinically Significant Topline Results for the Phase 2 REGEN-007 Trial Evaluating Rilparencel in Patients with Chronic Kidney Disease and Diabetes - GlobeNewsWire